Azacitidine + Ascorbic Acid for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 11 Jan 2018: Trial registered, NCT03397173
  2. 16 Mar 2018: Trial started, NCT03397173
  3. 16 Dec 2025: Trial registered, NCT07283900
  4. 11 Mar 2026: Trial started, NCT07283900

The trials

NCT03397173: TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

State
Completed
Phase
Phase 2
People
12 taking part
Started
16 Mar 2018
Primary completion
3 Jan 2021
Arms
Azacitidine + Ascorbic acid
Results
None posted
  1. 11 Jan 2018: Trial registered
  2. 16 Mar 2018: Trial started
  3. 21 Jan 2021: Trial completed

NCT07283900: Ascorbate in Myelodysplastic Syndrome

State
Suspended
Phase
Phase 2
People
38 planned
Started
11 Mar 2026
Primary completion
1 May 2028
Arms
High-Dose Ascorbate + Azacitidine
Results
None posted
  1. 16 Dec 2025: Trial registered
  2. 11 Mar 2026: Trial started
  3. 9 Oct 2026: Trial suspended

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.